The pitfalls of CA19-9: routine testing and comparison of two automated immunoassays in a reference oncology center.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  American Journal of Clinical Pathology

• Publication date

  2012-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1309/AJCPOPNPLLCYR07HPMID 22904141
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview

  2011cited by this paper
• Tumour marker requesting in primary care and the role of the laboratory

  2011cited by this paper
• First alert for recurrence during follow-up after potentially curative resection for colorectal carcinoma: CA 19-9 should be included in surveillance programs.

  2010cited by this paper
• Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report.

  2010cited by this paper
• Comparison of two different methods for CA19-9 antigen determination.

  2010cited by this paper
• Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype

  2010cited by this paper
• National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers.

  2010cited by this paper
• Tumor Marker Evolution: Comparison with Imaging for Assessment of Response to Chemotherapy in Patients with Colorectal Liver Metastases

  2010cited by this paper
• Comparison of three immunoassays for CA 19-9.

  2009cited by this paper
• Falsely elevated carbohydrate antigen 19-9 level due to heterophilic antibody interference but not rheumatoid factor: a case report

  2009cited by this paper
• How do we interpret an elevated carbohydrate antigen 19-9 level in asymptomatic subjects?

  2009cited by this paper
• Chemotherapy-induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer

  2009cited by this paper
• Biological variation and reference change values of CA 19‐9, CEA, AFP in serum of healthy individuals

  2008cited by this paper
• Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer.

  2007cited by this paper
• Interchangeability of measurements of CA 19-9 in serum with four frequently used assays: an update

  2007cited by this paper
• Carbohydrate antigen sialyl Lewis a--its pathophysiological significance and induction mechanism in cancer progression.

  2007cited by this paper
• Performance characteristics of five automated CA 19-9 assays.

  2007cited by this paper
• Persistent elevation of serum CA 19-9 with no evidence of malignant disease.

  2006cited by this paper
• Rheumatoid factor interference in the determination of carbohydrate antigen 19-9 (CA 19-9)

  2006cited by this paper
• Role of Serum Tumor Markers in Monitoring for Recurrence of Gastric Cancer Following Radical Gastrectomy

  2006cited by this paper
• The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study

  2003cited by this paper
• Human anti-animal antibody interferences in immunological assays.

  1999cited by this paper
• Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population.

  1999cited by this paper
• Etiology of Anti-Animal Antibodies and Mechanism of Interference in

  1999cited by this paper
• Cobas Core CA 19-9 II EIA: new CA 19-9 enzyme immunoassay with high correlation to radioimmunoassays.

  1997cited by this paper
• Serum tumor markers in monitoring patients: interpretation of results using analytical and biological variation.

  1996cited by this paper
• A prognostic value of CA 19-9 but not of CEA in patients with gastric cancer.

  1995cited by this paper
• Tumor antigens CA 19.9, CA 125, and CEA in carcinoma of the uterine cervix.

  1995cited by this paper
• Distribution of CA 19-9 in adenocarcinomas and transitional cell carcinomas. An immunohistochemical study of 527 cases.

  1993cited by this paper
• Tissue CA 125 and CA 19-9 in malignant, mixed mesodermal tumors of the uterus.

  1993cited by this paper
• The reliability of highly elevated CA 19-9 levels.

  1993cited by this paper
• A prospective study of tumor markers CA 125 and CA 19.9 in patients with epithelial ovarian carcinomas.

  1992cited by this paper
• The clinical utility of the CA 19-9 tumor-associated antigen.

  1990cited by this paper
• Serum levels of CA-50, CA-19.9, CA-125, neuron specific enolase and carcinoembryonic antigen in lung cancer and benign diseases of the lung.

  1989cited by this paper
• The detection of human pancreatic cancer‐associated antigen in the serum of cancer patients

  1987cited by this paper
• Quantitative and qualitative characterization of human cancer-associated serum glycoprotein antigens expressing fucosyl or sialyl-fucosyl type 2 chain polylactosamine.

  1986cited by this paper
• Expression of carbohydrate antigen 19-9 and stage-specific embryonic antigen 1 in nontumorous and tumorous epithelia of the human colon and rectum.

  1985cited by this paper
• Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin.

  1983cited by this paper
• A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II.

  1982cited by this paper

• Biosensor-driven innovation in CA19-9 cancer biomarker detection: current trends, technical challenges, and future directions towards point-of-care diagnostics

  2025cites this paper
• Survival prediction for CA19-9 non-producers with resected pancreatic cancer.

  2025cites this paper
• Comparative Study of Elevated CA19-9 Levels in Non-Gastrointestinal Tumors Patients: Evaluation of Different Immunoassay Methods and Analysis of Potential Interfering Factors

  2025influential citation
• Using Tumor Marker Gene Variants to Improve the Diagnostic Accuracy of DUPAN-2 and Carbohydrate Antigen 19-9 for Pancreatic Cancer

  2024cites this paper
• Real-Life Management of Pancreatic Cysts: Simplified Review of Current Guidelines

  2023cites this paper
• Surgical Considerations for Neoadjuvant Therapy for Pancreatic Adenocarcinoma

  2023cites this paper
• Case Report: Overcoming challenges in pancreatic cancer with liver metastases: a personalized therapeutic odyssey of TACE, ablation, and immunotherapy

  2023cites this paper
• Diagnostic Performance of a Tumor Marker Gene Test to Personalize Serum CA19–9 Reference Ranges

  2023cites this paper
• Green synthesis of copper iodide nanoparticles: gamma irradiation for spectroscopic sensing of cancer biomarker CA 19-9

  2023cites this paper
• Aberrant Glycosylation as Immune Therapeutic Targets for Solid Tumors

  2023cites this paper
• Clinical characteristics and outcomes in carbohydrate antigen 19-9 negative pancreatic cancer

  2022cites this paper
• Preoperative therapy for pancreatic adenocarcinoma—precision beyond anatomy

  2022cites this paper
• Lateral Flow Immunoassay Based on Time-Resolved Fluorescence Microspheres for Rapid and Quantitative Screening CA199 in Human Serum

  2022cites this paper
• Circulating tumor DNA for diagnosis, prognosis and treatment of gastrointestinal malignancies

  2022cites this paper
• Infection Masquerading as Recurrence of Pancreatic Ductal Adenocarcinoma: A Cautionary Tale

  2021cites this paper
• Translational and clinical aspects of pancreatic cancer

  2021cites this paper
• Biomolecular recognition of the glycan neoantigen CA19-9 by distinct antibodies

  2021cites this paper
• Non-Invasive Biomarkers for Earlier Detection of Pancreatic Cancer—A Comprehensive Review

  2021cites this paper
• Health risk assessment based on metal analysis of soil and crops in Al-Dakhla Oasis

  2021cites this paper
• Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma

  2021cites this paper
• Targeting CA 19-9 with a humanized monoclonal antibody at the time of surgery may decrease recurrence rates for patients undergoing resections for pancreatic cancer, cholangiocarcinoma and metastatic colorectal cancer.

  2020cites this paper
• Evaluation of 2 Commercially Systems for Detection of Serum Squamous Cell Carcinoma Antigen in Pan Squamous Cell Carcinoma

  2020cites this paper
• Pancreatic Cancer Prognostication: From Trousseau to Thrombelastography.

  2020cites this paper
• Immune-Directed Molecular Imaging Biomarkers.

  2020cites this paper
• Plasma Lysyl-tRNA Synthetase 1 (KARS1) as a Novel Diagnostic and Monitoring Biomarker for Colorectal Cancer

  2020cites this paper
• The tissue expression pattern of CA 19.9 is associated with oncological features in medullary thyroid carcinoma

  2020cites this paper
• Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter.

  2020cites this paper
• Directed Evolution of Therapeutic Antibodies Targeting Glycosylation in Cancer

  2020cites this paper
• Development of Quantitative Lateral Flow Strip Biosensors for the Detection of Cancer Biomarkers

  2019cites this paper
• Chemiluminescent dual-enzyme immunoassays capable of simultaneously quantifying carbohydrate antigen 19-9 and carcinoma embryonic antigen in a sample.

  2019cites this paper
• GI Surgery Annual

  2019cites this paper
• Tumor Markers in GI and HPB Cancers

  2019cites this paper
• Development of electrochemical biosensors for tumor marker determination towards cancer diagnosis: Recent progress

  2019cites this paper
• Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA

  2019cites this paper
• Computed Tomography–Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer

  2019cites this paper
• The Comparison Between Different Immunoassays for Serum Carbohydrate Antigen (CA 19-9) Concentration Measurement

  2018cites this paper
• Label-Free Biosensing Method for the Detection of a Pancreatic Cancer Biomarker Based on Dielectrophoresis Spectroscopy

  2018cites this paper
• Mucinous Tumours of the Pancreas

  2018cites this paper
• Circulating Mucins and Cytokeratins in Aggressive Thyroid Cancers

  2018cites this paper
• Imaging‐based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy

  2018cites this paper
• Cancer Antigen 72-4 for the Monitoring of Advanced Tumors of the Gastrointestinal Tract, Lung, Breast and Ovaries.

  2017cites this paper
• Serum carcinoembryonic antigen specifically increases among various serum markers of adenocarcinoma in hypohidrosis or conditions related to hypohidrosis

  2017cites this paper
• Existence of a squamous cell carcinoma antigen-immunoglobulin complex causes a deviation between squamous cell carcinoma antigen concentrations determined using two different immunoassays: first report of squamous cell carcinoma antigen coupling with immunoglobulin A

  2017cites this paper
• Development of quantitative immunochromatographic assay for rapid and sensitive detection of carbohydrate antigen 19–9 (CA 19–9) in human plasma

  2017cites this paper
• Serum reference interval of ARCHITECT alpha-fetoprotein in healthy Chinese Han adults: Sub-analysis of a prospective multi-center study.

  2017cites this paper
• Interfering Effect of Black Tea Consumption on Diagnosis of Pancreatic Cancer by CA 19-9

  2017cites this paper
• Evaluation of an Automated CLIA System for the Determination of Carbohydrate Antigen 19-9.

  2016cites this paper
• High Serum Level of CA 19-9 not Always Related to the Pancreas: An Asymptomatic Case of Highly Elevated CA 19-9 Related to Lung Adenocarcinoma

  2016cites this paper
• To be or not to be: A two years surveillance for a CA 19-9 persistent elevation before cancer diagnosis and bone metastases

  2016cites this paper
• Recommendations for the frequency of ordering laboratory testing

  2015cites this paper
• Programmed cell death 6 interacting protein (PDCD6IP) and Rabenosyn‐5 (ZFYVE20) are potential urinary biomarkers for upper gastrointestinal cancer

  2015cites this paper
• Review of Commonly Used Serum Tumor Markers and Their Relevance for Image Interpretation

  2015cites this paper
• The need for effective pancreatic cancer detection and management: a biomarker-based strategy

  2015cites this paper
• Evaluation of serum-based cancer biomarkers: a brief review from a clinical and computational viewpoint.

  2015cites this paper
• CA 19-9: Biochemical and Clinical Aspects.

  2015cites this paper
• Caution in a case of highly discrepant carbohydrate antigen 19-9 values in an apparently healthy patient taking spirulina: a case report

  2015cites this paper
• Post-treatment alterations of serum cancer antigen 125, cancer antigen 19.9 and carcinoembryonic antigen levels in patients with gynecological malignancies in a tertiary care hospital in eastern India

  2014cites this paper
• Significance of CEA and CA19-9 combination as a prognostic indicator and for recurrence monitoring in patients with stage II colorectal cancer.

  2014cites this paper
• Empfehlungen zur Häufigkeit der Anforderung von Laboruntersuchungen

  2014cites this paper
• CA 19-9: handle with care

  2013cites this paper